These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 21211583)

  • 1. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain.
    Farnsworth A; Cyr TD; Li C; Wang J; Li X
    Vaccine; 2011 Feb; 29(8):1529-33. PubMed ID: 21211583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention: Vaccine for all seasons.
    Schlütter J
    Nature; 2011 Nov; 480(7376):S6-8. PubMed ID: 22158298
    [No Abstract]   [Full Text] [Related]  

  • 3. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China.
    Li C; Shao M; Cui X; Song Y; Li J; Yuan L; Fang H; Liang Z; Cyr TD; Li F; Li X; Wang J
    Biologicals; 2010 Mar; 38(2):284-9. PubMed ID: 20074976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Composition of hemagglutinin and neuraminidase affects the antigen yield of influenza A(H1N1)pdm09 candidate vaccine viruses.
    Shirakura M; Kawaguchi A; Tashiro M; Nobusawa E
    Jpn J Infect Dis; 2013; 66(1):65-8. PubMed ID: 23429089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
    Settembre EC; Dormitzer PR; Rappuoli R
    J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.
    Schmeisser F; Vodeiko GM; Lugovtsev VY; Stout RR; Weir JP
    Vaccine; 2010 Mar; 28(12):2442-9. PubMed ID: 20074687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
    Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunology. Flu antibodies stir new hope for treatment, vaccine.
    Leslie M
    Science; 2009 Feb; 323(5918):1160. PubMed ID: 19251602
    [No Abstract]   [Full Text] [Related]  

  • 9. Construction and comparison of different source neuraminidase candidate vaccine strains for human infection with Eurasian avian-like influenza H1N1 virus.
    Liu L; Lu J; Zhou J; Li Z; Zhang H; Wang D; Shu Y
    Microbes Infect; 2017 Dec; 19(12):635-640. PubMed ID: 28859895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus.
    Loeffen WL; de Vries RP; Stockhofe N; van Zoelen-Bos D; Maas R; Koch G; Moormann RJ; Rottier PJ; de Haan CA
    Vaccine; 2011 Feb; 29(8):1545-50. PubMed ID: 21219983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
    Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of seasonal vaccine hemagglutinin subtype 1 (H1) epitopes in Mexican isolates of the new influenza A (H1N1) 2009 virus.
    Rodríguez-Alvarez M; Velasco-Velasco AM; Alvarez-Anell NJ; Jiménez-Corona ME; de León-Rosales SP
    Arch Med Res; 2009 Nov; 40(8):687-92. PubMed ID: 20304258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of influenza A vaccine virus by reverse genetic using chimeric HA and NA genes with an extended PR8 backbone.
    Medina J; Boukhebza H; De Saint Jean A; Sodoyer R; Legastelois I; Moste C
    Vaccine; 2015 Aug; 33(35):4221-7. PubMed ID: 26206270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel sequence-based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strains.
    Pan K; Subieta KC; Deem MW
    Protein Eng Des Sel; 2011 Mar; 24(3):291-9. PubMed ID: 21123189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementing sequence-based antigenic distance calculation into immunological shape space model.
    Anderson CS; Sangster MY; Yang H; Mariani TJ; Chaudhury S; Topham DJ
    BMC Bioinformatics; 2020 Jun; 21(1):256. PubMed ID: 32560624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants.
    Palker T; Kiseleva I; Johnston K; Su Q; Toner T; Szymkowiak C; Kwan WS; Rubin B; Petrukhin L; Wlochowski J; Monteiro J; Kraiouchkine N; DiStefano D; Rudenko L; Shaw A; Youil R
    Virus Res; 2004 Oct; 105(2):183-94. PubMed ID: 15351492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.